Eva Maria Rivera, APRN
Family · Las Vegas, NVNPI 1437780996
Payments from drug & device makers
Across 18 payments — averaging $52.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$311
- AbbVie$161
- Otsuka America Pharmaceutical, Inc.$125
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$100
- Eisai Inc.$45
- Novo Nordisk$42
- plus $154 from 6 others
What the payments were for
- Food & beverage$938100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 2 | $311 |
| AbbVie | 4 | $161 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $100 |
| Eisai Inc. | 2 | $45 |
| Novo Nordisk | 2 | $42 |
| EMD Serono, Inc. | 1 | $34 |
| Lundbeck LLC | 1 | $28 |
| Acera Surgical, Inc. | 1 | $27 |
| Johnson & Johnson | 1 | $24 |
| Biogen | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$311
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
- QULIPTA$122
- UBRELVY$122
How this compares
$938 in reported general payments places this provider in the 65th percentile of 1,501 family providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 25 | $5,201 |
| Ziprasidone Hcl | 12 | $812 |
| Olanzapine | 44 | $574 |
| Divalproex Sodium ErDivalproex Sodium | 17 | $289 |
| Gabapentin | 18 | $249 |
| Propranolol Hcl | 16 | $234 |
| Duloxetine Hcl | 24 | $176 |
| Prazosin Hcl | 19 | $136 |
| Mirtazapine | 22 | $127 |
| Bupropion XlBupropion Hcl | 28 | $117 |
| Alprazolam | 18 | $70 |
| Donepezil Hcl | 17 | $68 |
| Quetiapine Fumarate | 15 | $62 |
| Lorazepam | 16 | $46 |
| Sertraline Hcl | 19 | $39 |
Paid to pharmacies, not to this prescriber.
Other family in Las Vegas
- John PhoenixLas Vegas$281K
- Hollie TylerLas Vegas$118K
- Jon FaillaLas Vegas$74K
- Alex LapasaranLas Vegas$50K
- Kelly PapeshLas Vegas$44K
- Erin WilkinsonLas Vegas$43K
- Anna Melisa Lopez-SanglayLas Vegas$42K
- Bernard BlanksLas Vegas$26K
- Hillary DursteinLas Vegas$21K
- Victoria HughesLas Vegas$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.